The GPR55 agonist lysophosphatidylinositol relaxes rat mesenteric resistance artery and induces Ca2+ release in rat mesenteric artery endothelial cells

British Journal of Pharmacology

Volumn 172, Issue 12, 2015, Pages 3043-3057

  Alsuleimani, Y M ^a,b   Hiley, C R ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b SULTAN QABOOS UNIVERSITY   (Oman)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 1 [[6 (3 METHOXYESTRA 1,3,5(10) TRIEN 17BETA YL)AMINO]HEXYL] 1H PYRROLE 2,5 DIONE; 2 AMINOETHOXYDIPHENYLBORANE; 4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; CALCIUM ION; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CHARYBDOTOXIN; G PROTEIN COUPLED RECEPTOR; G PROTEIN COUPLED RECEPTOR 55; IBERIOTOXIN; LEVO ALPHA LYSOPHOSPHATIDYLINOSITOL; O 1918; POTASSIUM CHANNEL; RIMONABANT; THAPSIGARGIN; UNCLASSIFIED DRUG; VASODILATOR AGENT; 1-(6-((3-METHOXYESTRA-1,3,5(10)-TRIEN-17-YL)AMINO)HEXYL)-1H-PYRROLE-2,5-DIONE; 2 PYRROLIDONE DERIVATIVE; CALCIUM; CANNABINOID RECEPTOR; ESTRANE DERIVATIVE; GPR55 PROTEIN, RAT; INOSITOL 1,4,5 TRISPHOSPHATE; LYSOPHOSPHATIDYLINOSITOL; LYSOPHOSPHOLIPID; PHOSPHOLIPASE C;

ANIMAL CELL; ANIMAL TISSUE; ANTIHYPERTENSIVE ACTIVITY; ARTERIAL PRESSURE; ARTICLE; BLOOD VESSEL TONE; CALCIUM CELL LEVEL; CALCIUM SIGNALING; CALCIUM TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG MECHANISM; DRUG POTENTIATION; MALE; MESENTERIC ARTERY; NONHUMAN; POLYMERASE CHAIN REACTION; POTASSIUM TRANSPORT; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASODILATATION; AGONISTS; ANIMAL; DRUG EFFECTS; ENDOTHELIUM CELL; METABOLISM; WISTAR RAT;

ANIMALS; CALCIUM; ENDOTHELIAL CELLS; ESTRENES; INOSITOL 1,4,5-TRISPHOSPHATE; LYSOPHOSPHOLIPIDS; MALE; MESENTERIC ARTERIES; PYRROLIDINONES; RATS; RATS, WISTAR; RECEPTORS, CANNABINOID; RECEPTORS, G-PROTEIN-COUPLED; TYPE C PHOSPHOLIPASES; VASODILATOR AGENTS;

EID: 84930195220     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.13107     Document Type: Article

References (68)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013a). The Concise Guide to PHARMACOLOGY 2013/14: G Protein-Coupled Receptors. Br J Pharmacol 170: 1459-1581.
2. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013b). The Concise Guide to PHARMACOLOGY 2013/14: Enzymes. Br J Pharmacol 170: 1797-1867.
3. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Catterall WA, et al. (2013c). The Concise Guide to PHARMACOLOGY 2013/14: Ion Channels. Br J Pharmacol 170: 1607-1651.
4. AlSuleimani YM, (2011). An investigation into the actions of novel lipid signalling molecules in the vasculature. PhD thesis, University of Cambridge, Cambridge, UK.
5. AlSuleimani YM, Hiley CR, (2013). Mechanisms of vasorelaxation induced by oleoylethanolamide in the rat small mesenteric artery. Eur J Pharmacol 702: 1-11.
6. Balenga NA, Aflaki E, Kargl J, Platzer W, Schroder R, Blattermann S, et al. (2011). GPR55 regulates cannabinoid 2 receptor-mediated responses in human neutrophils. Cell Res 21: 1452-1469.
7. + current. J Biol Chem 278: 46188-46194.
8. Bleasdale JE, Bundy GL, Bunting S, Fitzpatrick FA, Huff RM, Sun FF, et al. (1989). Inhibition of phospholipase C dependent processes by U-73,122. Adv Prostaglandin Thromboxane Leukot Res 19: 590-593.
9. Bleasdale JE, Thakur NR, Gremban RS, Bundy GL, Fitzpatrick FA, Smith RJ, et al. (1990). Selective inhibition of receptor-coupled phospholipase C-dependent processes in human platelets and polymorphonuclear neutrophils. J Pharmacol Exp Ther 255: 756-768.
10. Bondarenko AI, (2014). Endothelial atypical cannabinoid receptor: do we have enough evidence? Br J Pharmacol 171: 5573-5588.
11. Bondarenko A, Waldeck-Weiermair M, Naghdi S, Poteser M, Malli R, Graier WF, (2010). GPR55-dependent and -independent ion signalling in response to lysophosphatidylinositol in endothelial cells. Br J Pharmacol 161: 308-320.
12. + channels in endothelial cells. Pflugers Arch 461: 177-189.
13. + channels. Pflugers Arch 462: 245-255.
14. Booden MA, Siderovski DP, Der CJ, (2002). Leukemia-associated Rho guanine nucleotide exchange factor promotes G alpha q-coupled activation of RhoA. Mol Cell Biol 22: 4053-4061.
15. Brahler S, Kaistha A, Schmidt VJ, Wolfle SE, Busch C, Kaistha BP, et al. (2009). Genetic deficit of SK3 and IK1 channels disrupts the endothelium-derived hyperpolarizing factor vasodilator pathway and causes hypertension. Circulation 119: 2323-2332.
16. Brown AJ, Hiley CR, (2009). Is GPR55 an anandamide receptor? Vitam Horm 81: 111-137.
17. Brown AJ, Wise A, (2001). Identification of modulators of GPR55 activity. GlaxoSmithKline Patent No. WO0186305.
18. Daly C, Ross R, Whyte J, Henstridge C, Irving A, McGrath J, (2010). Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and 'cannabinoid-like' receptors in small arteries. Br J Pharmacol 159: 787-796.
19. Dora KA, Gallagher NT, McNeish A, Garland CJ, (2008). Modulation of endothelial cell KCa3.1 channels during endothelium-derived hyperpolarizing factor signaling in mesenteric resistance arteries. Circ Res 102: 1247-1255.
20. α12/13-induced signals to Rho GTPase. Cell Signal 16: 201-209.
21. Falasca M, Silletta MG, Carvelli A, Di Francesco AL, Fusco A, Ramakrishna V, et al. (1995). Signalling pathways involved in the mitogenic action of lysophosphatidylinositol. Oncogene 10: 2113-2124.
22. Falasca M, Iurisci C, Carvelli A, Sacchetti A, Corda D, (1998). Release of the mitogen lysophosphatidylinositol from H-Ras-transformed fibroblasts; a possible mechanism of autocrine control of cell proliferation. Oncogene 16: 2357-2365.
23. Ford LA, Roelofs AJ, Anavi-Goffer S, Mowat L, Simpson DG, Irving AJ, et al. (2010). A role for L-α-lysophosphatidylinositol and GPR55 in the modulation of migration, orientation and polarization of human breast cancer cells. Br J Pharmacol 160: 762-771.
24. Fukao M, Hattori Y, Kanno M, Sakuma I, Kitabatake A, (1996). Structural differences in the ability of lysophospholipids to inhibit endothelium-dependent hyperpolarization by acetylcholine in rat mesenteric arteries. Biochem Biophys Res Commun 227: 479-483.
25. Garthwaite J, Southam E, Boulton CL, Nielsen EB, Schmidt K, Mayer B, (1995). Potent and selective inhibition of nitric oxide-sensitive guanylyl cyclase by 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one. Mol Pharmacol 48: 184-188.
26. α12/13- and rho-dependent activation of phospholipase C-ε by lysophosphatidic acid and thrombin receptors. Mol Pharmacol 69: 2068-2075.
27. α13. Science 280: 2112-2114.
28. Heemskerk JW, Farndale RW, Sage SO, (1997). Effects of U73122 and U73343 on human platelet calcium signalling and protein tyrosine phosphorylation. Biochim Biophys Acta 1355: 81-88.
29. 2+ signaling and NFAT activation. FASEB J 23: 183-193.
30. Henstridge CM, Balenga NA, Schroder R, Kargl JK, Platzer W, Martini L, et al. (2010). GPR55 ligands promote receptor coupling to multiple signalling pathways. Br J Pharmacol 160: 604-614.
31. Hiley CR, Ford WR, (2004). Cannabinoid pharmacology in the cardiovascular system: potential protective mechanisms through lipid signalling. Biol Rev 79: 187-205.
32. Hiley CR, Kaup SS, (2007). GPR55 and the vascular receptors for cannabinoids. Br J Pharmacol 152: 559-561.
33. Hoi PM, (2007). Cannabinoid receptor pharmacology in the rat small mesenteric artery. PhD thesis, University of Cambridge, Cambridge, UK.
34. Hoi PM, Hiley CR, (2006). Vasorelaxant effects of oleamide in rat small mesenteric artery indicate action at a novel cannabinoid receptor. Br J Pharmacol 147: 560-568.
35. Ishizaki T, Naito M, Fujisawa K, Maekawa M, Watanabe N, Saito Y, et al. (1997). p160ROCK, a Rho-associated coiled-coil forming protein kinase, works downstream of Rho and induces focal adhesions. FEBS Lett 404: 118-124.
36. Jensen PE, (1996). Calphostin C-sensitive enhancements of force by lysophosphatidylinositol and diacylglycerols in mesenteric arteries from the rat. Br J Pharmacol 119: 15-22.
37. Johns DG, Behm DJ, Walker DJ, Ao Z, Shapland EM, Daniels DA, et al. (2007). The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br J Pharmacol 152: 825-831.
38. Katan M, (2005). New insights into the families of PLC enzymes: looking back and going forward. Biochem J 39: 7-9.
39. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
40. + channels in human mesenteric artery: a single-cell reverse transcriptase-polymerase chain reaction and electrophysiological study in situ. Circ Res 87: 496-503.
41. Lauckner JE, Jensen JB, Chen HY, Lu HC, Hille B, Mackie K, (2008). GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc Natl Acad Sci U S A 105: 2699-2704.
42. Ledoux J, Taylor MS, Bonev AD, Hannah RM, Solodushko V, Shui B, et al. (2008). Functional architecture of inositol 1,4,5-trisphosphate signaling in restricted spaces of myoendothelial projections. Proc Natl Acad Sci U S A 105: 9627-9632.
43. Lim JC, Kania KD, Wijesuriya H, Chawla S, Sethi JK, Pulaski L, et al. (2008). Activation of beta-catenin signalling by GSK-3 inhibition increases p-glycoprotein expression in brain endothelial cells. J Neurochem 106: 1855-1865.
44. Lockhart LK, McNicol A, (1999). The phospholipase C inhibitor U73122 inhibits phorbol ester-induced platelet activation. J Pharmacol Exp Ther 289: 721-728.
45. Ca channels in cerebral EDHF-mediated dilations. Am J Physiol Heart Circ Physiol 285: 1590-1599.
46. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
47. McNaughton E, Ho V, (2013). Investigating the role of the putative cannabinoid receptor GPR55 in vascular control in mice. Available at: http://www.pa2online.org/abstracts/vol11issue1abst016.pdf (accessed 30/03/2015).
48. Offertaler L, Mo FM, Batkai S, Liu J, Begg M, Razdan RK, et al. (2003). Selective ligands and cellular effectors of a G protein-coupled endothelial cannabinoid receptor. Mol Pharmacol 63: 699-705.
49. Oka S, Nakajima K, Yamashita A, Kishimoto S, Sugiura T, (2007). Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem Biophys Res Commun 362: 928-934.
50. Oka S, Toshida T, Maruyama K, Nakajima K, Yamashita A, Sugiura T, (2009). 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J Biochem 145: 13-20.
51. Oka S, Kimura S, Toshida T, Ota R, Yamashita A, Sugiura T, (2010). Lysophosphatidylinositol induces rapid phosphorylation of p38 mitogen-activated protein kinase and activating transcription factor 2 in HEK293 cells expressing GPR55 and IM-9 lymphoblastoid cells. J Biochem 147: 671-678.
52. Pawson AJ, Sharman JL, Benson HE, Faccenda E, Alexander SP, Buneman OP, et al.; NC-IUPHAR (2014). The IUPHAR/BPS Guide to PHARMACOLOGY: an expert-driven knowledge base of drug targets and their ligands. Nucleic Acids Res 42 (Database Issue): D1098-D1106.
53. Rosker C, Meur G, Taylor EJ, Taylor CW, (2009). Functional ryanodine receptors in the plasma membrane of RINm5F pancreatic beta-cells. J Biol Chem 284: 5186-5194.
54. Ca) and connexins: possible relationship to vasodilator function? J Anat 209: 689-698.
55. Santos CF, Caprio MA, Oliveira EB, Salgado MC, Schippers DN, Munzenmaier DH, et al. (2003). Functional role, cellular source, and tissue distribution of rat elastase-2, an angiotensin II-forming enzyme. Am J Physiol Heart Circ Physiol 285: 775-783.
56. Seifert JP, Wing MR, Snyder JT, Gershburg S, Sondek J, Harden TK, (2004). RhoA activates purified phospholipase C-epsilon by a guanine nucleotide-dependent mechanism. J Biol Chem 279: 47992-47997.
57. Shi TJ, Liu SX, Hammarberg H, Watanabe M, Xu ZQ, Hokfelt T, (2008). Phospholipase Cβ3 in mouse and human dorsal root ganglia and spinal cord is a possible target for treatment of neuropathic pain. Proc Natl Acad Sci U S A 105: 20004-20008.
58. Stahle M, Veit C, Bachfischer U, Schierling K, Skripczynski B, Hall A, et al. (2003). Mechanisms in LPA-induced tumor cell migration: critical role of phosphorylated ERK. J Cell Sci 116: 3835-3846.
59. α12 activates Rho GTPase through tyrosine-phosphorylated leukemia-associated RhoGEF. Proc Natl Acad Sci U S A 100: 733-738.
60. Tominaga T, Ishizaki T, Narumiya S, Barber DL, (1998). p160ROCK mediates RhoA activation of Na-H exchange. EMBO J 17: 4712-4722.
61. Wagner JA, Varga K, Jarai Z, Kunos G, (1999). Mesenteric vasodilation mediated by endothelial anandamide receptors. Hypertension 33: 429-434.
62. 2+ signaling in endothelial cells via GPR55 by protection against CB1-receptor-triggered repression. J Cell Sci 121: 1704-1717.
63. q signaling complex. Science 330: 974-980.
64. White R, Hiley CR, (1998). The actions of the cannabinoid receptor antagonist, SR 141716A, in the rat isolated mesenteric artery. Br J Pharmacol 125: 689-696.
65. Wing MR, Snyder JT, Sondek J, Harden TK, (2003). Direct activation of phospholipase C-ε by Rho. J Biol Chem 278: 41253-41258.
66. + channel, IKCa1: a potential immunosuppressant. Proc Natl Acad Sci U S A 97: 8151-8156.
67. Yin H, Chu A, Li W, Wang B, Shelton F, Otero F, et al. (2009). Lipid G-protein-coupled receptor ligand identification Using β-arrestin PathHunter assay. J Biol Chem 284: 12328-12338.
68. Zhang X, Maor Y, Wang JF, Kunos G, Groopman JE, (2010). Endocannabinoid-like N-arachidonoyl serine is a novel pro-angiogenic mediator. Br J Pharmacol 160: 1583-1594.